Oncology Companion Diagnostic Market Size & Growth Forecast 2027–2036, By Segments (Product & Services, End-use, Technology, Disease Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Oncology Companion Diagnostic Market size was worth USD 5.9 billion in 2026 and is poised to grow at a 8.55% CAGR between 2027 and 2036, surpassing USD 13.4 billion by 2036. The industry revenue for 2027 is assessed at USD 6.32 billion.
Get more details on this report
Request Free Sample ReportOncology Companion Diagnostic Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 42.58% share in 2026, supported by precision oncology ecosystems, molecular testing infrastructure, and widespread use of biomarker-based treatment pathways.
- Asia Pacific is projected to grow at a 10.06% CAGR, driven by expanding molecular diagnostics access and increasing adoption of personalized cancer treatment approaches.
Segment Momentum
- Products accounted for 64.16% of the market in 2026 because assay kits, instruments, and diagnostic tools are essential for identifying biomarker-defined patient populations and supporting routine oncology testing workflows.
- Pathology/Diagnostic Laboratories are the fastest-growing end users due to increasing demand for specialized biomarker testing, high-throughput workflows, and advanced diagnostic expertise as precision oncology expands.
Market Expansion Drivers
- Increasing cancer prevalence driving demand for precision oncology diagnostic solutions globally.
- Expansion of comprehensive genomic profiling enabling precise targeted cancer therapy selection.
- Rising adoption of liquid biopsy technologies enabling non-invasive cancer patient stratification.
Leading Market Participants
- Leading companies in the oncology companion diagnostic market include Agilent Technologies, Inc. (United States), Illumina, Inc. (United States), QIAGEN N.V. (Germany), Thermo Fisher Scientific Inc. (United States), Foundation Medicine, Inc. (United States), Myriad Genetics, Inc. (United States), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux SA (France), Abbott Laboratories (United States), Guardant Health, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.9 billion
- 2027 Estimated Market Size: USD 6.32 billion.
- Projected Market Size: USD 13.4 billion by 2036
- Growth Forecast: 8.55% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Product (Product & Services) | Hospital (End-use) | Polymerase Chain Reaction (PCR) (Technology) | Non-small Cell Lung Cancer (Disease Type)
- Emerging Opportunity Segment: Services (Product & Services) | Pathology/Diagnostic Laboratory (End-use) | Next-generation Sequencing (NGS) (Technology) | Breast Cancer (Disease Type)
Market Growth Drivers and Industry Trends
Increasing cancer prevalence driving demand for precision oncology diagnostic solutions globally
Increasing cancer prevalence is driving the oncology companion diagnostic market as healthcare providers and pharmaceutical developers place greater emphasis on identifying molecular characteristics that can guide treatment decisions. Companion diagnostic solutions enable clinicians to determine whether patients possess specific biomarkers associated with the potential effectiveness or suitability of targeted therapies, supporting more individualized treatment strategies. The growing complexity of cancer biology is also increasing the need for diagnostic approaches capable of distinguishing molecularly distinct patient groups rather than relying solely on conventional disease classification. As oncology care increasingly incorporates biomarker-based treatment selection, demand for diagnostic testing is expanding across clinical and drug development settings.
Expansion of comprehensive genomic profiling enabling precise targeted cancer therapy selection
Expansion of comprehensive genomic profiling will propel the oncology companion diagnostic market by allowing multiple genetic alterations to be evaluated within a broader diagnostic assessment. These profiling approaches can identify actionable mutations, alterations, and molecular signatures that may influence the selection of targeted therapies, particularly in cancers with diverse genomic profiles. Their growing use in oncology research and clinical practice is also helping physicians evaluate treatment options when patients have complex or evolving disease characteristics. In parallel, pharmaceutical developers benefit from broader genomic characterization during clinical development because it supports the identification and stratification of patient populations for biomarker-driven therapies.
Rising adoption of liquid biopsy technologies enabling non-invasive cancer patient stratification
Rising adoption of liquid biopsy technologies will drive the oncology companion diagnostic market by providing a less invasive approach for obtaining tumor-related molecular information from biological samples. Liquid biopsy can support the detection and monitoring of circulating tumor-derived biomarkers, making it useful for assessing molecular changes when repeated tissue biopsies are difficult or impractical. Its potential role in identifying actionable alterations, evaluating treatment response, and monitoring disease evolution is increasing interest among oncology researchers and healthcare providers. The ability to obtain molecular insights through minimally invasive testing is particularly relevant for patient stratification and longitudinal monitoring in targeted cancer treatment pathways.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing cancer prevalence driving demand for precision oncology diagnostic solutions globally | 2.30% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expansion of comprehensive genomic profiling enabling precise targeted cancer therapy selection | 1.90% | High | North America, Europe, Asia Pacific | High | Mid Term |
| Rising adoption of liquid biopsy technologies enabling non-invasive cancer patient stratification | 1.50% | High | North America, Europe, Asia Pacific | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
In the oncology companion diagnostic market, North America held the largest share of 42.58% in 2026, reflecting the region's mature precision oncology ecosystem, sophisticated diagnostic infrastructure, and strong integration of biomarker testing into cancer treatment pathways. The growing use of targeted therapies has increased the need for diagnostic tests that identify patients most likely to benefit from specific treatments, while established clinical research capabilities support continued development and adoption. Favorable healthcare infrastructure and increasing emphasis on personalized cancer care further strengthen demand for companion diagnostics.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, supported by expanding cancer care infrastructure, increasing adoption of precision medicine, and greater availability of advanced diagnostic technologies. Healthcare systems across the region are progressively strengthening molecular testing capabilities, creating opportunities for companion diagnostics to become more integrated into oncology treatment decisions. Rising awareness of biomarker-driven therapies, expanding clinical research activity, and continued healthcare modernization are expected to accelerate regional adoption.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Testing StandardsGermany prioritizes standardized molecular testing to support personalized cancer treatment across hospital and reference laboratory networks. Adoption of validated companion diagnostics is reinforced by strong collaboration between healthcare providers and life sciences companies.
France 🇫🇷
Clinical Pathway IntegrationFrance is integrating companion diagnostics more closely into oncology care pathways through multidisciplinary cancer programs. The country's emphasis on evidence-based treatment selection supports wider utilization of biomarker-driven diagnostic solutions.
Italy 🇮🇹
Hospital Testing EnhancementItaly continues expanding molecular diagnostic capacity within oncology centers to support personalized treatment strategies. Greater adoption of companion diagnostic assays reflects increasing collaboration between hospitals, diagnostic laboratories, and pharmaceutical companies.
Japan 🇯🇵
Targeted Therapy AlignmentJapan advances oncology companion diagnostics alongside expanding use of targeted cancer therapies. Japanese healthcare providers continue integrating biomarker testing into clinical workflows to improve treatment selection and support individualized patient management.
South Korea 🇰🇷
Genomic Diagnostics ExpansionSouth Korea is strengthening oncology companion diagnostic capabilities through investments in genomic medicine and advanced laboratory technologies. Healthcare providers increasingly incorporate molecular testing to guide targeted therapies and improve clinical decision-making.
United States 🇺🇸
Precision Oncology AdoptionThe U.S. continues to expand oncology companion diagnostics through routine genomic profiling and close alignment between pharmaceutical developers and diagnostic companies. Clinical laboratories increasingly integrate biomarker-driven testing into treatment selection across multiple cancer indications.
Segment Leadership and Growth Trends
Oncology Companion Diagnostic Market Share (%), by Product & Services, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct & Services Segment Analysis: Product (Largest Segment) vs Services (Fastest-Growing Segment)
The product segment led the oncology companion diagnostic market with a 64.16% share in 2026, supported by the essential role of diagnostic assays, kits, and related testing platforms in identifying biomarkers that guide targeted cancer therapies. Companion diagnostic products enable healthcare providers to determine patient eligibility for specific treatments, improve therapy selection, and support more personalized approaches to oncology care. Growing emphasis on precision medicine and biomarker-based treatment strategies continues to strengthen demand for reliable diagnostic products across cancer care pathways.
The services segment is advancing at the fastest pace as oncology testing becomes increasingly dependent on specialized laboratory capabilities, interpretation, validation, and ongoing diagnostic support. Healthcare providers and research organizations are seeking external expertise to manage complex biomarker testing workflows, particularly as precision oncology expands into more sophisticated molecular and genomic applications. Increasing clinical reliance on accurate diagnostic interpretation and the need to integrate testing into personalized treatment decisions are supporting greater adoption of companion diagnostic services.
End-use Segment Analysis: Hospital (Largest Segment) vs Pathology/Diagnostic Laboratory (Fastest-Growing Segment)
Hospitals accounted for the largest share of the oncology companion diagnostic market at 54.3% in 2026, reflecting their central role in cancer diagnosis, treatment planning, and administration of targeted therapies. Hospitals provide integrated oncology services where diagnostic testing can be closely linked with clinical evaluation and treatment decisions, supporting the routine use of companion diagnostics. The growing adoption of precision medicine within hospital-based cancer care is further reinforcing demand for biomarker testing and related diagnostic capabilities.
Pathology/diagnostic laboratories are emerging as the fastest-growing end-use segment as increasingly complex oncology testing requires specialized infrastructure and technical expertise. These laboratories support healthcare systems by providing molecular, genomic, and biomarker analysis that can complement hospital-based diagnostic services. Rising demand for accurate treatment selection, greater outsourcing of specialized testing, and the expanding role of laboratory-based precision diagnostics are expected to accelerate adoption within this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product & Services | Product, Services | Product | Services |
| End-use | Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center | Hospital | Pathology/Diagnostic Laboratory |
| Technology | Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), Immunohistochemistry (IHC), In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH), Others | Polymerase Chain Reaction (PCR) | Next-generation Sequencing (NGS) |
| Disease Type | Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Leukemia, Melanoma, Prostate Cancer, Others | Non-small Cell Lung Cancer | Breast Cancer |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Major players in the oncology companion diagnostic market:
1. Agilent Technologies Inc. (United States)
2. Illumina Inc. (United States)
3. QIAGEN N.V. (Germany)
4. Thermo Fisher Scientific Inc. (United States)
5. Foundation Medicine Inc. (United States)
6. Myriad Genetics Inc. (United States)
7. F. Hoffmann-La Roche Ltd (Switzerland)
8. bioMérieux SA (France)
9. Abbott Laboratories (United States)
10. Guardant Health Inc. (United States)
Rapid progress in precision medicine is driving significant transformation in the oncology companion diagnostic market. Industry stakeholders are increasingly integrating liquid biopsy technologies, AI-assisted interpretation tools, and biomarker-focused testing solutions to improve diagnostic accuracy and treatment selection. Partnerships supporting clinical validation and regulatory alignment are also playing a major role in accelerating commercialization and expanding personalized oncology applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Agilent Technologies Inc. (United States) | |||||||
| Illumina Inc. (United States) | |||||||
| QIAGEN N.V. (Germany) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Foundation Medicine Inc. (United States) | |||||||
| Myriad Genetics Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| bioMérieux SA (France) | |||||||
| Abbott Laboratories (United States) | |||||||
| Guardant Health Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Ventana Medical Systems | May-25 | The U.S. FDA approved the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer (NSCLC) patients eligible for treatment with Emrelis (telisotuzumab vedotin). This immunohistochemistry-based test detects MET protein overexpression, facilitating the selection of patients most likely to respond to this targeted therapy based on Phase 2 clinical trial evidence. |
| Foundation Medicine | Jan-25 | The U.S. FDA approved FoundationOne CDx as the first companion diagnostic for tovorafenib (OJEMDA) to treat pediatric patients aged six months and older with relapsed or refractory low-grade glioma. The test identifies BRAF fusions, rearrangements, and V600 mutations, enabling clinicians to match patients with this targeted therapy for a condition that previously lacked standardized diagnostic-driven treatment options. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Oncology Companion Diagnostic Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Biomarker Type | Genetic Biomarkers, Protein Biomarkers, Genomic Biomarkers, Epigenetic Biomarkers, Multi-Biomarker Panels |
| Therapy Class | Targeted Therapy, Immunotherapy, Hormonal Therapy, Chemotherapy, Antibody-Drug Conjugates |
| Specimen Type | Tissue Biopsy, Blood & Plasma, Cytology Samples, Bone Marrow, Other Liquid Biopsies |
Oncology Companion Diagnostic Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Precision Oncology Testing Adoption Roadmap |
|
| Drug–Diagnostic Co-Development Pipeline Assessment |
|
| Reimbursement and Market Access Benchmarking |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the oncology companion diagnostic market?
What is the forecasted size of the oncology companion diagnostic industry?
How is comprehensive genomic profiling reshaping demand in the oncology companion diagnostic market?
Why is liquid biopsy gaining momentum in oncology companion diagnostics?
Why do products dominate the oncology companion diagnostic market?
What is fueling growth in pathology and diagnostic laboratories within the oncology companion diagnostic market?
Why is North America the leading region for oncology companion diagnostics?
How is Asia Pacific accelerating growth in the oncology companion diagnostic market?
Which companies are driving growth in the oncology companion diagnostic landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization